PMCB News and Press, PharmaCyte Biotech Inc. From 09/13/23

PharmaCyte Biotech Inc. (PMCB) is expected to report for quarter end 2023-07-31

2023-06-15 12:31:57 ET Cell therapy developer PharmaCyte Biotech ( NASDAQ: PMCB ) announced Thursday the completion of its previously announced tender offer to purchase up to 7.8M shares of the company’s common stock. Disclosing its results, the Las Vegas, Nevada-based bi...

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of ...

2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...

Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3....

Summary Meta Platforms, Inc. announced a whopping $40 billion share repurchase program. In 2022, Meta repurchased 160 million shares worth $27.9 billion. Its competitor, Pinterest, Inc. also announced a $500 million share buyback last week. Tech giant, Meta Platforms, Inc....

PharmaCyte Biotech ( NASDAQ: PMCB ) has authorized a second share repurchase program to repurchase up to $10M of it’s outstanding common stock. This share repurchase authorization is effective immediately for a two-year period. The company expects to fund the program wi...

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box ® for potential development of cellular therapies for cancer, diabetes and...

PharmaCyte Biotech ( NASDAQ: PMCB ) on Friday announced that its CEO Kenneth Waggoner had stepped down and said its board had authorized a business review committee to evaluate strategic opportunities for the company. Las Vegas, Nev. based PMCB is a biotech that is eva...

PharmaCyte Biotech ( NASDAQ: PMCB ), a biotech focused on cellular therapies, announced Friday that the company’s board has tasked its Business Review Committee with evaluating business opportunities to generate optimum value for shareholders. In addition, PMCB anno...